RxDoctor Payments Data

Tammie Copp

Adult Health · Corning, NYNPI 1104427871

Payments from drug & device makers

$4,968in general payments, 2019–2025

Across 176 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$711
  • Regeneron Healthcare Solutions, Inc.$574
  • Grifols USA, LLC$228
  • Harmony Biosciences LLC$216
  • plus $460 from 6 others

What the payments were for

  • Food & beverage$4,77996%
  • Education$1894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,968 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$49,992
Medicare patients
295
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter474$389,320
Breztri AerosphereBudesonide/Glycopyr/Formoterol184$143,189
Breo ElliptaFluticasone/Vilanterol93$54,774
NucalaMepolizumab13$48,047
Stiolto RespimatTiotropium Br/Olodaterol Hcl78$44,410
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$38,924
Spiriva RespimatTiotropium Bromide24$23,246
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$17,183
SymbicortBudesonide/Formoterol Fumarate29$14,940
Albuterol Sulfate HfaAlbuterol Sulfate258$9,917
Bevespi AerosphereGlycopyrrolate/Formoterol Fum19$9,887
Incruse ElliptaUmeclidinium Bromide23$9,828
Advair HfaFluticasone Propion/Salmeterol15$8,277
AirsupraAlbuterol Sulfate/Budesonide16$7,278
DuleraMometasone/Formoterol14$4,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$1,552$545,549676 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra$1,227$175,294248 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$711$67,656102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in Corning

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →